We utilized two mouse strains, BALB/c and C57BL/6, and two tumor models, the 4T1 metastatic breast cancer model and TRAMP-Tg spontaneous prostate cancer model, to evaluate whether the MVA-TWIST/TRICOM vaccine platform could induce anti-Twist immune responses leading to antitumor efficacy. This evidence concerns the gene TWIST1 and Familial prostate cancer.